Key result
A survey of 275 German specialists found that while 76% use LMWH for acute cancer-associated VTE, only 55% continue it for 3-6 months, indicating frequent deviation from guideline recommendations.
Cross-Sectional (n=275)
Yes
Real-world practice patterns among German specialists for long-term VTE treatment in cancer patients frequently deviate from guideline recommendations for LMWH use.
Answers are grounded in this paper and cite their sources.
Common guideline deviations in cancer-associated VTE care observed; hypothesis-generating for adherence barriers and outcomes.
BACKGROUND: Venous thromboembolism (VTE) is a serious threat for cancer patients. Guidelines recommend low-molecular-weight heparin (LMWH) for prophylaxis and treatment, but it is unknown to what extent specialists adhere to these recommendations. This survey assesses the current approach to patients with cancer-associated VTE in Germany. MATERIALS AND METHODS: A questionnaire was sent out to members of the DGHO (Deutsche Gesellschaft für Hämatologie und Onkologie), the BNHO (Berufsverband Niedergelassener Hämatologen und Onkologen) and the DGP (Deutsche Gesellschaft für Phlebologie). For most questions, more than 1 answer was possible; therefore, the total sum of percentages may exceed 100%. RESULTS: 275 specialists responded. 76% of them treat acute VTE with LMWH while 22% switch to oral treatments (vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs)) during the acute phase. For the next 3-6 months, 55% of the specialists continue LMWH, while 31% switch to VKAs and 33% to NOACs. Among those who continue LMWH for 3-6 months, 37% continue at the full dose, 26% reduce to 75% of the initial dose, and 40% even to 50%. Important factors guiding treatment decisions were the need for injections and the availability of a partner/spouse (LMWH), the need for laboratory controls (VKAs), and the number of other oral medications (NOACs). CONCLUSION: This survey reveals that practice patterns often do not follow the guideline recommendations with respect to the use of LMWH for long-term treatment of VTE in cancer patients.
No takes yet. Share an insight, caveat, or question.
Matzdorff et al. (2016) conducted a cross-sectional in Cancer-associated venous thromboembolism (n=275). Survey of practice patterns was evaluated on Treatment choices for acute and long-term VTE. A survey of 275 German specialists found that while 76% use LMWH for acute cancer-associated VTE, only 55% continue it for 3-6 months, indicating frequent deviation from guideline recommendations.
Synapse has enriched 10 related papers. Consider them for comparative context: